BRAF V600E mutations occur in approximately 2%–5% of human gastric cancers and are associated with microsatellite instability and better response to immunotherapy, making this comparison between KRAS and BRAF particularly relevant for understanding pathway-specific effects (Sim et al., 2019). This evidence concerns the gene BRAF and gastric cancer.